Liminal BioSciences Inc. [NASDAQ: LMNL] closed the trading session at $5.07 on 12/21/20. The day’s price range saw the stock hit a low of $4.40, while the highest price level was $7.07. The company report on December 18, 2020 that Notice from the Office of the Secretary – Ontario Securities Commission.
FIRST GLOBAL DATA LTD., GLOBAL BIOENERGY RESOURCES INC., NAYEEM ALLI, MAURICE AZIZ, HARISH BAJAJ, AND ANDRE ITWARU, File No. 2019-22.
TORONTO, Dec. 17, 2020 /CNW/ – Take notice that the hearing in the above named matter scheduled to be heard on December 18, 2020 will not proceed as scheduled.
The stocks have a year to date performance of -39.50 percent and weekly performance of 21.58 percent. The stock has been moved at -55.33 percent over the last six months. The stock has performed -7.99 percent around the most recent 30 days and changed -55.25 percent over the most recent 3-months.
If compared to the average trading volume of 602.60K shares, LMNL reached to a volume of 16344249 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Liminal BioSciences Inc. [LMNL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LMNL shares is $4.26 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LMNL stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Liminal BioSciences Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 21, 2020.
The Average True Range (ATR) for Liminal BioSciences Inc. is set at 0.57, with the Price to Sales ratio for LMNL stock in the period of the last 12 months amounting to 57.31. The Price to Book ratio for the last quarter was 4.23, with the Price to Cash per share for the same quarter was set at 0.96.
LMNL stock trade performance evaluation
Liminal BioSciences Inc. [LMNL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 21.58. With this latest performance, LMNL shares dropped by -7.99% in over the last four-week period, additionally sinking by -55.33% over the last 6 months – not to mention a drop of -9.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LMNL stock in for the last two-week period is set at 57.83, with the RSI for the last a single of trading hit 68.18, and the three-weeks RSI is set at 50.30 for Liminal BioSciences Inc. [LMNL]. The present Moving Average for the last 50 days of trading for this stock 4.95, while it was recorded at 4.32 for the last single week of trading, and 9.22 for the last 200 days.
Liminal BioSciences Inc. [LMNL]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Liminal BioSciences Inc. [LMNL] shares currently have an operating margin of -2423.08 and a Gross Margin at -136.97. Liminal BioSciences Inc.’s Net Margin is presently recorded at -4754.89.
Return on Total Capital for LMNL is now -114.82, given the latest momentum, and Return on Invested Capital for the company is -223.53. Return on Equity for this stock declined to -940.75, with Return on Assets sitting at -173.43. When it comes to the capital structure of this company, Liminal BioSciences Inc. [LMNL] has a Total Debt to Total Equity ratio set at 46.06. Additionally, LMNL Total Debt to Total Capital is recorded at 31.54, with Total Debt to Total Assets ending up at 28.51. Long-Term Debt to Equity for the company is recorded at 37.79, with the Long-Term Debt to Total Capital now at 25.87.
Reflecting on the efficiency of the workforce at the company, Liminal BioSciences Inc. [LMNL] managed to generate an average of -$585,777 per employee. Receivables Turnover for the company is 0.30 with a Total Asset Turnover recorded at a value of 0.04.Liminal BioSciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.20.
Liminal BioSciences Inc. [LMNL]: Insider Ownership positions
There are presently around $13 million, or 10.80% of LMNL stock, in the hands of institutional investors. The top three institutional holders of LMNL stocks are: CONSONANCE CAPITAL MANAGEMENT LP with ownership of 3,084,627, which is approximately -6.166% of the company’s market cap and around 67.67% of the total institutional ownership; ATOM INVESTORS LP, holding 53,033 shares of the stock with an approximate value of $0.27 million in LMNL stocks shares; and VIRTU FINANCIAL LLC, currently with $75000.0 in LMNL stock with ownership of nearly New of the company’s market capitalization.
Positions in Liminal BioSciences Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 6 institutional holders increased their position in Liminal BioSciences Inc. [NASDAQ:LMNL] by around 60,532 shares. Additionally, 10 investors decreased positions by around 257,187 shares, while 1 investors held positions by with 2,859,822 shares. The mentioned changes placed institutional holdings at 3,177,541 shares, according to the latest SEC report filing. LMNL stock had 3 new institutional investments in for a total of 31,156 shares, while 5 institutional investors sold positions of 11,453 shares during the same period.